CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805

A Morgans;Y Chen;D Jarrard;M Carducci;G Liu;M Eisenberger;E Plimack;A Bryce;J Garcia;R Dreicer;N Vogelzang;J Picus;D Shevin;M Hussain;R DiPaola;D Cella;C Sweeney Prostate May 10. doi: 10.1002/pros.24369. Online ahead of print

PMid: PMID35538398

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

J Hearn;CJ Sweeney;N Almassi;C Reichard;CA Reddy;H Li;B Hobbs;D Jarrard;Y-H Chen;R Dreicer;J Garcia;M Carducci;R DiPaola;N Sharifi JAMA Oncology Feb 13;6(4):e196496

PMid: PMID32053149 | PMC number: PMC7042830

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

A Bryce;Y Chen;G Liu;M Carducci;D Jarrard;J Garcia;R Dreicer;M Hussain;M Eisenberger;E Plimack;N Vogelzang;R DiPaola;L Harshman;C Sweeney European Urology Oncology Dec;3(6):717-724

PMid: PMID32807727 | PMC number: PMC7738423

HSD3B1 and Overall Survival (OS) in Men with Low-Volume (LV) Metastatic Prostate Cancer (PCa) Treated with Androgen Deprivation Therapy (ADT) or Chemohormonal Therapy in the CHAARTED Randomized Trial

J Hearn;C Sweeney;N Almassi;C Reichard;C Reddy;B Hobbs;DF Jarrard;Y-H Chen;R Dreicer;JA Garcia;M Carducci;R DiPaola;N Sharifi J Clin Oncol 37(suppl; abstr 5020); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion

Quality of life (QOL) during treatment with chemohormonal therapy: analysis of ECOG 3805 chemohormonal androgen ablation randomized trial in prostate cancer (CHAARTED)

A Morgans;Y Chen;C Sweeney;D Jarrad;E Plimack;B Gartrell;M Carducci;M Hussain;J Garcia;D Cella;R DiPaola;L Patrick-Miller Journal of Clinical Oncology, Apr 10;36(11):1088-1095; Mar 9 [Epub ahead of print]

PMid: PMID29522362 | PMC number: PMC5891128

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 trial

CE Kyriakopoulos;Y Chen;M Carducci;G Liu;DF Jarrard;M Eisenberger;Y Wong;N Hahn;M Koli;M Cooney;R Dreicer;N Vogelzang;J Picus;D Shevrin;M Hussain;J Garcia;R DiPaola;C Sweeney Journal of Clinical Oncology Apr 10;36(11):1080-1087; Jan 31:JCO2017753657 [Epub ahead of print]

PMid: PMID29384722 | PMC number: PMC5891129

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial

A Bryce;Y Chen;G-F Liu;M Carducci;DF Jarrard;JA Garcia;R Dreicer;M Hussain;MA Eisenberger;M Kohli;NM Hahn;E Plimack;N Vogelzang;J Picus;R DiPaola;L Harshman;C Sweeney J Clin Oncol 36, 2018 (suppl; abstr 5046); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL)

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

LC Harshman;YH Chen;G Liu;M Carducci;D Jarrard;R Dreicer;N Hahn;JA Garcia;M Hussain;D Shevrin;M Eisenberger;M Kohli;ER Plimack;M Cooney;N Vogelzang;J Picus;R DiPaola;C Sweeney Journal of Clinical Oncology Feb 1;36(4):376-382

PMid: PMID29261442 | PMC number: PMC5805480

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

G Gravis;J Boher;YH Chen;G Liu;K Fizazi;M Carducci;S Oudard;F Joly;DM Jarrard;M Soulie;M Eisenberger;M Habibian;R Dreicer;JA Garcia;M Hussain;M Kohli;N Vogelzang;J Picus;R DiPaola;CJ Sweeney European Urology Jun;73(6):847-855

PMid: PMID29475737 | PMC number: PMC6010352

Impact of metformin on overall and prostate cancer-specific survival in the chemohormonal adjuvant chemotherapy CHAARTED trial (http://meetinglibrary.asco.org/content/179540-197)

D Jarrard;YH Chen;G Liu;M Carducci;M Eisenberger;YN Wong;L Patrick-Miller;N Hahn;M Kohli;M Cooney;R Dreicer;NJ Vogelzang;J Picus;D Shevrin;M Hussain;J Garcia;R Dipaola;C Sweeney Journal of Clinical Oncology 35, 2017 (suppl 6S; abstract 181); ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), poster

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)

LC Harshman;Y-H Chen;G Liu;M Carducci;D Jarrard;M Eisenberger;Y-N Wong;N Hahn;M Kohli;M Conney;R Dreicer;N Vogelzang;J Picus;D Shevrin;M Hussain;J Garcia;R DiPaola;C Sweeney Journal of Clinical Oncology 35, 2017 (suppl 6S; abstract 137); ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), poster

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa)

M Pomerantz;V Wang;P Kantoff;W Xie;M Kohli;G-S M Lee;E Wang;Y-H Chen;N Hahn;D Jarrard;G Liu;J Garcia;M Carducci;R DiPaola;M Freedman;C Sweeney Journal of Clinical Oncology 34, 2016 (suppl; abstr 1540); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

C Sweeney;Y-H Chen;G Liu;M Carducci;D Jarrard;M Eisenberger;Y Wong;L Patrick-Miller;N Hahn;M Kohli;M Conney;R Dreicer;N Vogelzang;J Picus;D Shevrin;M Hussain;J Garcia;R Dipaola Annals of Oncology vol. 27, 2016 Supp 6,abst. 720PD; European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark), (Annals of Oncology), poster

Chemohormonal therapy in metastatic hormone- sensitive prostate cancer

C Sweeney;Y-H Chen;M Carducci;G Yiu;D Jarrard;WN Wong;MA Eisenberger;N Hahn;M Kohli;MM Cooney;R Dreicer;N Vogelzang;J Picus;D Shevrin;M Hussain;J Garcia;R DiPaola New England Journal of Medicine, Aug 20;373(8):737-746

PMid: PMID26244877 | PMC number: PMC4562797

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial

C Sweeney;H-Y Chen;MA Carducci;G Liu;D Jarrad;M Eisenberger;Y-N Wong;NM Hahn;M Kohli;N Vogelzang;MM Cooney;R Dreicer;J Picus;DH Shevrin;M Hussain;JA Garcia;RS DiPaola Journal of Clinical Oncology 32:5s (suppl; abstr LBA2); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);